Hepatic steatosis associated with metabolic dysfunction and the risk of 24 specific cancers
This article was originally published here
Metabolism. December 13, 2021: 154955. doi: 10.1016 / j.metabol.2021.154955. Online ahead of print.
BACKGROUND: Fatty liver disease associated with metabolic dysfunction (MAFLD) is a significant health problem closely associated with multiple metabolic dysfunctions. The association between MAFLD and cancer risk is still unknown.
METHODS: Participants in the UK Biobank study were diagnosed with the presence of MAFLD at baseline. A multivariable Cox regression model was performed to examine associations of MAFLD with incident events in 24 specific cancers.
RESULTS: We included 352,911 people (37.2% with MAFLD), of whom 23,345 developed cancer. Compared with non-MAFLD, MAFLD was significantly associated with 10 of 24 cancers examined, including the uterine body (hazard ratio [HR] = 2.36, 95% CI 1.99-2.80), gallbladder (2.20, 1.14-4.23), liver (1.81, 1.43-2.28), kidney (1.77, 1.49-2.11), thyroid (1.69, 1.20-2.38), esophagus (1.48, 1.25-1.76), pancreas (1.31 , 1.10-1.56), bladder (1.26, 1.11-1.43), breast (1.19, 1.11-1.27) and colorectal and anal cancers ( 1.14, 1.06-1.23). The associations of MAFLD with cancers of the liver, esophagus, pancreas, colorectal, anal and bladder and malignant melanoma were reinforced in men, and the associations with cancers of the kidney, thyroid and kidney. lung increased in women. The associations of MAFLD with the risk of liver, kidney and thyroid cancers remained significant after further adjustment for waist circumference or body mass index and the number of components of the metabolic syndrome based on the major models. The PNPLA3 risk-increasing allele rs738409 significantly enhanced the association of MAFLD with the risk of liver and kidney cancer.
CONCLUSION: MAFLD is associated with an increased risk of a range of cancers, but the effect varies considerably by site. MAFLD deserves higher priority in the current cancer prevention scheme.
IDPM: 34915036 | DOI: 10.1016 / j.metabol.2021.154955